[1]朱 娜a,陈 博b,张小艳c,等.血清S100-β蛋白对闭合性颅脑损伤患者诊断及预后临床价值的研究[J].现代检验医学杂志,2017,32(05):59-61.[doi:10.3969/j.issn.1671-7414.2017.05.016]
 ZHU Naa,CHEN Bob,ZHANG Xiao-yanc,et al.Clinical Value of Serum S100-beta Protein in the Diagnosis and Prognosis of Patients with Closed Craniocerebral Injury[J].Journal of Modern Laboratory Medicine,2017,32(05):59-61.[doi:10.3969/j.issn.1671-7414.2017.05.016]
点击复制

血清S100-β蛋白对闭合性颅脑损伤患者诊断及预后临床价值的研究()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年05期
页码:
59-61
栏目:
论著
出版日期:
2017-11-02

文章信息/Info

Title:
Clinical Value of Serum S100-beta Protein in the Diagnosis and Prognosis of Patients with Closed Craniocerebral Injury
文章编号:
1671-7414(2017)05-059-03
作者:
朱 娜a陈 博b张小艳c奚逢瑜c张利侠c
陕西省人民医院a.科研处; b.神经外科; c.检验科,西安 710068
Author(s):
ZHU NaaCHEN BobZHANG Xiao-yancXI Feng-yuc ZHANG Li-xiac
a.Scientific Research Division; b.Department of Neurosurgery; c.Department of Clinical Laboratory,Shaanxi Provincial People's Hospital,Xi'an 710068,China
关键词:
S100-β蛋白 颅脑损伤 生化标志物
分类号:
R651.15; R446.112
DOI:
10.3969/j.issn.1671-7414.2017.05.016
文献标志码:
A
摘要:
目的 检测闭合性颅脑损伤患者血清中S100-β蛋白水平,分析其对该病诊断及预后评估的临床价值。方法 采用免疫定量分析法检测31例健康对照组、40例重型颅脑损伤患者和34例轻型颅脑损伤患者入院时S100-β蛋白水平、受试者工作特征曲线(ROC)、预后GOS相关性分析,探讨其对闭合性颅脑损伤的辅助诊断效能。结果 对照组、轻型及重型闭合性颅脑损伤组S100-β蛋白水平分别为0.137±0.025,0.192±0.038和0.276±0.097ng/ml。与对照组相比,轻型(F=0.126,P=0.008)及重型闭合性颅脑损伤组(F=38.17,P=0.001)血清S100-β蛋白水平均显著升高,差异有统计学意义(P<0.01)。轻型与重型颅脑损伤组间血清S100-β水平差异有统计学意义(P<0.05)。血清S100-β蛋白鉴别对照组与轻型颅脑损伤组的AUC为0.870(95% CI:0.776~0.964,P<0.01); S100-β蛋白鉴别健康对照组与重型颅脑损伤组的AUC为0.914(95% CI:0.850~0.978,P<0.01)。颅脑损伤患者血清S100-β蛋白水平与预后GOS评分呈负相关(r=-0.792,P<0.01)。结论 S100-β蛋白在轻型及重型闭合性颅脑损伤患者血清中显著升高,且与预后GOS评分呈负相关,可用于颅脑损伤的辅助诊断及预后评估。
Abstract:
Abstract:Objective To detect the level of S100-β protein in the serum of patients with closed craniocerebral injury and analyze its clinical value to assess the diagnosis and prognosis of the disease.Methods The expression of quantitative analysis method to detect 31 cases of healthy control group,40 cases of patients with severe craniocerebral injury and 34 cases of craniocerebral injury patients on admission S100-β protein level by the receiver operating characteristic curve(ROC)analysis,to explore the correlation between the prognosis of GOS,closed craniocerebral injury diagnosis efficacy.Results In the control group,mild andsevere closed craniocerebral injury group S100-β protein levels were 0.137±0.025,0.192±0.038 and 0.276 ±0.097 ng/ml,respectively.Compared with the control group(F=0.126,P=0.008),light and heavy closed craniocerebral injury group(F=38.17,P=0.001)of serum S100-β protein levels were significantly increased,the difference was statistically significant(P<0.01).There were significant differences in the level of serum S100-β light and heavy craniocerebral injury group(P<0.05).Serum S100-βprotein differential control groupand brain injury group AUC 0.870(95%CI:0.776~0.964,P<0.01).S100-βprotein identification in healthy control group with severe craniocerebral injury group AUC was 0.914(95% CI:0.850~0.978,P< 0.01).The score was negatively correlated with serum S100-β protein level and the prognosis of craniocerebral injury in GOS(r=-0.792,P<0.01).Conclusion S100-β protein significantly increased in serum of light and heavy closed craniocerebral injury patients,and negatively correlated with the GOS score of patients,can be used for the auxiliary diagnosis and prognosis of craniocerebralinjury.

参考文献/References:

[1] 卜晓敏,宋佳希,樊春荔,等.颅脑损伤患者血清αⅡ血影蛋白裂解产物(SBDPs)水平检测的临床意义[J].现代检验医学杂志,2017,32(1):9-11,15. Bu XM,Song JX,Fan CL,et al.Study on serum levels of SBDPs and their clinical significance in patients with traumatic brain injury[J].Journalof Modern Laboratory Medicine,2017,32(1):9-11,15.
[2] 侯明山,蔺鹏祯,杨 军,等.血浆和肽素水平与脑外伤患者病情严重程度相关性研究[J].现代检验医学杂志,2016,31(4):98-99,103. Hou MS,Lin PZ,Yang J,et al.Correlation study on plasma copeptinlevels and disease severity degree of patients with brain injury[J].Journal of Modern Laboratory Medicine,2016,31(4):98-99,103.
[3] Zongo D,Ribereau-Gayon R,Masson F,et al.S100-B protein as a screening tool for the early assessment of minor head injury[J].Annals of EmergencyMedicine,2012,59(3):209-218.
[4] Preusser M,Capper D,Ilhan-Mutlu A,et al.Brain metastases:pathobiology and emerging targeted therapies[J].Acta Neuropathol,2012,123(2):205-222.
[5] Pang X,Min J,Liu L,et al.S100B protein as a possible participant in the brain metastasis of NSCLC[J].Med Oncol,2012,29(4):2626-2632.
[6] Tolan NV,Vidal-Folch N,Algeciras-Schimnich A,et al.Individualized correction of neuron-specific enolase(NSE)measurement in hemolyzed serum samples[J].Clin Chim Acta,2013,424(4546):216-221.
[7] Pfortmueller CA,Drexel C,Krahenmann-Muller S,et al.S-100B concentrations are a predictor of decreased survival in patients with major trauma independently of head injury[J].PLos One,2016,11(3):e0152822.
[8] Beaudeux JL,Laribi S.S100B protein serum level as a biomarker of minorhead injury[J].Ann Biol Clin(Paris),2013,71(1):71-78.
[9] Koh SX,Lee JK.S100B as a marker for brain damage and blood-brain barrier disruption following exercise[J].Sports Med,2014,44(3):369-385.
[10] Astrand R,Undén J,Romner B.Clinical use of the calcium-binding S100B protein[J].Methods Mol Biol,2013(963):373-384.
[11] Egea-Guerrero JJ,Revuelto-Rev J,Murillo-Cabezas F,et al.Accuracyof the S100β protein as a marker of brain damage in traumatic brain injury[J].Brain Inj,2012,26(1):76-82.
[12] Thelin EP,Johannesson L,Nelson D,et al.S100B is an important outcomepredictor in traumatic brain injury[J].J Neurotrauma,2013,30(7):519-528.

备注/Memo

备注/Memo:
基金项目:陕西省科学技术研究发展计划[2011K12-76],西安市科技局科学发展计划项目[2016046SF/YX02(3)]。 作者简介:朱 娜(1982-),女,硕士,主治医师,主要研究方向为免疫学检验与临床疾病研究,E-mail:happybabyegg@163.com。 通讯作者:张利侠(1970-)女,硕士,主任技师,主要研究方向为免疫与微生物学检验。
更新日期/Last Update: 1900-01-01